Dyne Therapeutics (NASDAQ:DYN) Research Coverage Started at Robert W. Baird

Robert W. Baird assumed coverage on shares of Dyne Therapeutics (NASDAQ:DYN) in a research note issued to investors on Friday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $46.00 target price on the stock.

A number of other analysts have also recently commented on DYN. Chardan Capital reaffirmed a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Royal Bank of Canada started coverage on Dyne Therapeutics in a research note on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 price target on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $53.00 price objective on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Finally, Stifel Nicolaus boosted their target price on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $50.42.

Dyne Therapeutics Trading Up 0.5 %

Shares of DYN stock opened at $25.73 on Friday. Dyne Therapeutics has a 1-year low of $11.51 and a 1-year high of $47.45. The stock has a market cap of $2.62 billion, a price-to-earnings ratio of -7.23 and a beta of 1.09. The stock has a 50-day moving average of $30.39 and a 200-day moving average of $35.26.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Sell-side analysts forecast that Dyne Therapeutics will post -3.45 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $65,632.08. Following the sale, the insider now directly owns 201,685 shares in the company, valued at $5,671,382.20. The trade was a 1.14 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Carlo Incerti sold 16,500 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $28.73, for a total transaction of $474,045.00. The disclosure for this sale can be found here. Insiders have sold a total of 180,046 shares of company stock valued at $6,300,265 over the last 90 days. Insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of DYN. FMR LLC boosted its stake in Dyne Therapeutics by 69.7% in the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after purchasing an additional 3,707,734 shares during the period. RTW Investments LP lifted its holdings in shares of Dyne Therapeutics by 6.8% in the third quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after buying an additional 431,503 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Dyne Therapeutics by 47.3% in the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock valued at $244,755,000 after acquiring an additional 2,189,339 shares during the period. RA Capital Management L.P. grew its stake in Dyne Therapeutics by 5.5% during the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after acquiring an additional 331,940 shares in the last quarter. Finally, State Street Corp grew its stake in Dyne Therapeutics by 13.8% during the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after acquiring an additional 440,890 shares in the last quarter. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.